As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
24 Analysts have issued a Nurix Therapeutics Inc forecast:
24 Analysts have issued a Nurix Therapeutics Inc forecast:
| Aug '25 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | 84 84 | 
         
      
        
        48%
      
      
        
        48%
      
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -263 -263 | 
         
      
        
        47%
      
      
        
        47%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -267 -267 | 
         
      
        
        38%
      
      
        
        38%
      
 
        
       | 
      |
| Net Profit | -245 -245 | 
         
      
        
        38%
      
      
        
        38%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
| Head office | United States | 
| CEO | Arthur Sands | 
| Employees | 286 | 
| Founded | 2009 | 
| Website | www.nurixtx.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


